🇺🇸 FDA
Patent

US 11166985

Materials and methods for engineering cells and uses thereof in immuno-oncology

granted A61KA61K2239/48A61K38/00

Quick answer

US patent 11166985 (Materials and methods for engineering cells and uses thereof in immuno-oncology) held by CRISPR THERAPEUTICS AG expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2239/48, A61K38/00, A61K40/11, A61K40/31